BR0113301A - Composição de vacina em dose sólida oral - Google Patents

Composição de vacina em dose sólida oral

Info

Publication number
BR0113301A
BR0113301A BR0113301-2A BR0113301A BR0113301A BR 0113301 A BR0113301 A BR 0113301A BR 0113301 A BR0113301 A BR 0113301A BR 0113301 A BR0113301 A BR 0113301A
Authority
BR
Brazil
Prior art keywords
vaccine
vaccines
vaccine composition
oral solid
solid dose
Prior art date
Application number
BR0113301-2A
Other languages
English (en)
Inventor
Vincent Vande-Velde
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BR0113301A publication Critical patent/BR0113301A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO DE VACINA EM DOSE SóLIDA ORAL". A presente invenção refere-se a novas formulações de vacina apropriadas para administração oral. As formulações de vacina estão em uma forma sólida compreendendo antígeno e excipiente apropriado que, após inserção na boca, dissolve rapidamente na saliva, liberando assim a vacina na boca. Especificamente, a forma sólida pode consistir de uma hóstia de vacina que é formada de uma solução líquida ou suspensão por sublimação, preferivelmente sublimação por liofilização. Vacinas preferidas são as contendo antígenos que são derivados de patógenos que normalmente infectam o hospedeiro através de uma membrana mucosal, ou as vacinas que compreendem ainda um antiácido. Vacinas particularmente preferidas são vacinas em combinação que compreendem mais do que um antígeno e mais preferivelmente, quando os antígenos são de mais do que um patógeno.
BR0113301-2A 2000-08-15 2001-08-14 Composição de vacina em dose sólida oral BR0113301A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020089.9A GB0020089D0 (en) 2000-08-15 2000-08-15 Vaccine Composition
PCT/IB2001/001711 WO2002013858A1 (en) 2000-08-15 2001-08-14 Oral solid dose vaccine

Publications (1)

Publication Number Publication Date
BR0113301A true BR0113301A (pt) 2003-07-15

Family

ID=9897656

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113301-2A BR0113301A (pt) 2000-08-15 2001-08-14 Composição de vacina em dose sólida oral

Country Status (17)

Country Link
US (1) US20040013695A1 (pt)
EP (1) EP1309344A1 (pt)
JP (1) JP2004506020A (pt)
KR (1) KR20030031978A (pt)
CN (1) CN1842345A (pt)
AU (2) AU2001286168B2 (pt)
BR (1) BR0113301A (pt)
CA (1) CA2424160A1 (pt)
GB (1) GB0020089D0 (pt)
HU (1) HUP0301697A3 (pt)
IL (1) IL154404A0 (pt)
MX (1) MXPA03001392A (pt)
NO (1) NO20030713L (pt)
NZ (1) NZ524164A (pt)
PL (1) PL362481A1 (pt)
WO (1) WO2002013858A1 (pt)
ZA (1) ZA200301210B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050118138A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
US20050226894A1 (en) * 2002-01-15 2005-10-13 Jensen-Jarolim Erika Oral vaccination
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2004075875A1 (en) 2003-02-28 2004-09-10 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CA2542332C (en) 2003-10-16 2013-03-12 Stephen John Ralph Immunomodulating compositions and uses therefor
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
CA2624503A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
US20110111023A1 (en) 2007-09-11 2011-05-12 Kobenhavns Universitet Prevention of type 1 diabetes by administration of gliadin
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
AR083361A1 (es) 2010-10-08 2013-02-21 Scherer Technologies Inc R P Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
WO2012103464A2 (en) * 2011-01-28 2012-08-02 Brian Pulliam Oral thin film vaccine preparation
JP6253161B2 (ja) * 2012-03-05 2017-12-27 デ スタート デル ネーデルランデン， ヴェルト． ドール デ ミニステル ヴァン ヴイダブリューエス ミニステリー ヴァン ボルクスゲツォントヘイト， ベルジーン エン シュポルトＤｅ Ｓｔａａｔ Ｄｅｒ Ｎｅｄｅｒｌａｎｄｅｎ， Ｖｅｒｔ． Ｄｏｏｒ Ｄｅ Ｍｉｎｉｓｔｅｒ Ｖａｎ Ｖｗｓ Ｍｉｎｉｓｔｅｒｉｅ Ｖａｎ Ｖｏｌｋｓｇｅｚｏｎｄｈｅｉｄ， Ｗｅｌｚｉｊｎ Ｅｎ Ｓｐｏｒｔ 乾燥された生物学的材料を安定化するための方法及び組成物
WO2015013549A1 (en) * 2013-07-25 2015-01-29 Invado Pharmaceuticals, LLC Treating oral inflammation, injury or pain
EA201691348A1 (ru) * 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют Однофлаконные вакцинные составы
EP2952200A1 (en) 2014-06-04 2015-12-09 Alk-Abelló A/S Allergen for prophylactic treatment of allergy
TW201722472A (zh) * 2015-11-27 2017-07-01 Nitto Denko Corp 口腔內投與用疫苗醫藥組合物及口腔內投與用疫苗醫藥組合物之製造方法
WO2017090769A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4636385A (en) * 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection
GB9722682D0 (en) * 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
WO2001012797A2 (en) * 1999-08-17 2001-02-22 Smithkline Beecham Biologicals S.A. Method of separating rotavirus variants and live attenuated rotavirus vaccine
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신

Also Published As

Publication number Publication date
AU2001286168B2 (en) 2004-09-23
AU8616801A (en) 2002-02-25
NO20030713L (no) 2003-04-11
MXPA03001392A (es) 2004-12-13
WO2002013858A1 (en) 2002-02-21
US20040013695A1 (en) 2004-01-22
HUP0301697A2 (hu) 2003-08-28
NO20030713D0 (no) 2003-02-14
HUP0301697A3 (en) 2004-11-29
ZA200301210B (en) 2004-03-12
IL154404A0 (en) 2003-09-17
PL362481A1 (en) 2004-11-02
KR20030031978A (ko) 2003-04-23
CN1842345A (zh) 2006-10-04
CA2424160A1 (en) 2002-02-21
EP1309344A1 (en) 2003-05-14
GB0020089D0 (en) 2000-10-04
NZ524164A (en) 2004-10-29
JP2004506020A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
BR0113301A (pt) Composição de vacina em dose sólida oral
ES2331952T3 (es) Fraccion de quil a con baja toxicidad y su uso.
BRPI0208301A8 (pt) vacinas de ácido nucléico para prevenção de infecção por flavivírus
BR112022024248A2 (pt) Vacinas de combinação à base de ácido nucleico
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
ES2649020T3 (es) Vacuna inactivada del virus del dengue con adyuvante libre de aluminio
KR20130112790A (ko) 백신 조성물
ES2210495T3 (es) Iscom o matriz de iscom que comprende una sustancia dirigida especificamente a las mucosas y un antigeno.
HUP0400445A2 (hu) Új vakcinakészítmények
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
PT1820512E (pt) Vacina viva modificada melhorada contra brsv
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
AR052625A1 (es) Nueva composicion
JP2011045374A (ja) ワクチン
US20040047882A1 (en) Adjuvant for vaccines
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
BR112013009255B1 (pt) composição sólida de vacina oral de dissolução rápida
JP2003507040A5 (pt)
BR0312474A (pt) Partìcula viral adjuvante
JP2023099200A (ja) アジュバントおよび該アジュバントを含むワクチン
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
JP7046848B2 (ja) 弱毒化突然変異体ジカウイルスをコードするゲノム配列
BR112012022059B1 (pt) Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa
BR9915946A (pt) Preparações contendo partìculas similares a vìrus como imunopotenciadores administrados através da mucosa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2021 DE 29/09/2009.